Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Biotech companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in United KingdomLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under its name, each linked to the record.
As of Nov 15, 2026, FDA's public records list Kiniksa Pharmaceuticals (UK) with 1 drug application.
Drug applications: 1
Latest Records
Newest first across sources; each opens the record
FDA's databases did not answer. Reload in a moment.
Payments to Doctors (Open Payments)
What 2 reporting entities in this group reported paying US doctors and teaching hospitals each year; see every company
2025: $0.8MGeneral $0.0M · Research $0.8M
2024: $2.8MGeneral $1.7M · Research $1.1M
2023: $2.8MGeneral $0.8M · Research $2.0M
2022: $2.9MGeneral $0.4M · Research $2.5M
2021: $2.7MGeneral $0.3M · Research $2.4M
Orphan Designations (FDA)
2 designations since 1983, 1 approved for the designated use, matched by the sponsor's name; see all orphan designations
mavrilimumabTreatment of Giant Cell Arteritis · Sep 14, 2020
ArcalystTreatment of pericarditis · Jul 14, 2020 · approved Mar 18, 2021
Names and Identifiers
Appears as
KINIKSA PHARMACEUTICALS (UK), LTD.
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.How this page is built
